Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an ‘Off-the-Shelf’ Cancer Immunotherapy Developed Using Nouscom’s Proprietary Viral Vector Platform

Nouscom announced that Janssen Research & Development, LLC received US FDA clearance for its Investigational New Drug (IND) candidate VAC85135, an off-the-shelf, viral vector-based cancer vaccine for an oncologic indication.